Chip Davis, president and CEO of the Generic Pharmaceutical Association (GPhA) offered praise of a study published on May 9, 2016 in the Journal of the American Medical Association ( JAMA ) Internal Medicine . The new study revealed that from 2010 2012, in the United States, moOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.